Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Biotech
Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…
BMY
Deeply undervalued
BRISTOL MYERS SQUIBB CO
Price$63.64
Model IV$174.33
P/IV0.33
Discount 63%
Return to IV: +173.9%
Market implies -7.4%/yr
vs model +6.1% · below model
BNGO
Deeply undervalued
Bionano Genomics, Inc.
Price$1.56
Model IV$4.48
P/IV0.28
Discount 65%
Return to IV: +187.0%
Market implies -23.0%/yr
vs model +12.2% · below model
BNR
Valuation N/A
Burning Rock Biotech Ltd
Price$12.28
Model IV—
P/IV—
Limited data — see page
BNTC
Valuation N/A
Benitec Biopharma Inc.
Price$12.08
Model IV—
P/IV—
Market implies +147.0%/yr
BNTX
Valuation N/A
BioNTech SE
Price$96.73
Model IV—
P/IV—
Limited data — see page
BOLD
Valuation N/A
Boundless Bio, Inc.
Price$2.81
Model IV—
P/IV—
Limited data — see page
BOLT
Deeply undervalued
Bolt Biotherapeutics, Inc.
Price$3.95
Model IV$28.19
P/IV0.19
Discount 86%
Return to IV: +613.7%
Market implies -42.8%/yr
vs model +50.0% · below model
BRNS
Valuation N/A
Barinthus Biotherapeutics plc.
Price$0.74
Model IV—
P/IV—
Market implies +5.3%/yr
vs model +15.0% · below model
BRTX
Valuation N/A
BioRestorative Therapies, Inc.
Price$2.67
Model IV—
P/IV—
Market implies +49.8%/yr
vs model +50.0% · in line
BSTZ
Valuation N/A
BlackRock Science & Technology Term Trust
Price$31.04
Model IV—
P/IV—
Limited data — see page
BTAI
Valuation N/A
BioXcel Therapeutics, Inc.
Price$0.05
Model IV—
P/IV—
Market implies +12.5%/yr
vs model +15.0% · in line
BYSI
Valuation N/A
BeyondSpring Inc.
Price$0.76
Model IV—
P/IV—
Market implies +30.5%/yr
vs model +15.0% · above model
CABA
Valuation N/A
Cabaletta Bio, Inc.
Price$2.73
Model IV—
P/IV—
Limited data — see page
CADL
Valuation N/A
Candel Therapeutics, Inc.
Price$10.55
Model IV—
P/IV—
Market implies +144.9%/yr
vs model +2.0% · above model
CAI
Deeply undervalued
Caris Life Sciences, Inc.
Price$24.34
Model IV$37.69
P/IV0.44
Discount 35%
Return to IV: +54.8%
Market implies -5.8%/yr
vs model +50.0% · below model
CALC
Valuation N/A
CalciMedica, Inc.
Price$1.98
Model IV—
P/IV—
Limited data — see page
CAMP
Valuation N/A
Camp4 Therapeutics Corp
Price$4.25
Model IV—
P/IV—
Market implies +35.3%/yr
vs model +50.0% · below model
CANF
Valuation N/A
Can-Fite BioPharma Ltd.
Price$2.33
Model IV—
P/IV—
Market implies +30.1%/yr
vs model +2.0% · above model
CAPR
Valuation N/A
CAPRICOR THERAPEUTICS, INC.
Price$8.56
Model IV—
P/IV—
Market implies +43.5%/yr
vs model +15.0% · above model
CBIO
Valuation N/A
CRESCENT BIOPHARMA, INC.
Price$19.41
Model IV—
P/IV—
Market implies +17.0%/yr
vs model +50.0% · below model
CBUS
Valuation N/A
Cibus, Inc.
Price$1.57
Model IV—
P/IV—
Market implies +49.8%/yr
vs model +5.0% · above model
CCCC
Valuation N/A
C4 Therapeutics, Inc.
Price$3.51
Model IV—
P/IV—
Market implies +67.0%/yr
vs model +2.0% · above model
CCEL
Deeply undervalued
CRYO CELL INTERNATIONAL INC
Price$4.40
Model IV$12.21
P/IV0.28
Discount 64%
Return to IV: +177.5%
Market implies -11.8%/yr
vs model +5.5% · below model
CDT
Valuation N/A
CDT Equity Inc.
Price$0.25
Model IV—
P/IV—
Limited data — see page
CDTTW
Valuation N/A
CDT Equity Inc.
Price$0.01
Model IV—
P/IV—
Limited data — see page
CDXS
Valuation N/A
CODEXIS, INC.
Price$1.47
Model IV—
P/IV—
Market implies +46.9%/yr
vs model +0.0% · above model
CELC
Valuation N/A
Celcuity Inc.
Price$83.45
Model IV—
P/IV—
Limited data — see page
CELU
Deeply overvalued
Celularity Inc
Price$1.41
Model IV$0.63
P/IV1.60
Premium +124%
Return to IV: -55.3%
Market implies +6.3%/yr
vs model +5.6% · in line
CELZ
Valuation N/A
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Price$0.96
Model IV—
P/IV—
Market implies +92.0%/yr
vs model +2.0% · above model
CERT
Overvalued
Certara, Inc.
Price$8.40
Model IV$6.76
P/IV0.86
Premium +24%
Return to IV: -19.5%
Market implies +10.5%/yr
vs model +10.6% · in line
CGEM
Valuation N/A
Cullinan Therapeutics, Inc.
Price$20.59
Model IV—
P/IV—
Market implies +58.0%/yr
vs model +15.0% · above model
CGEN
Deeply undervalued
COMPUGEN LTD
Price$2.47
Model IV$8.67
P/IV0.30
Discount 72%
Return to IV: +251.0%
Market implies -1.7%/yr
vs model +25.0% · below model
CGON
Valuation N/A
CG Oncology, Inc.
Price$72.35
Model IV—
P/IV—
Market implies +78.2%/yr
vs model +50.0% · above model
CGTX
Valuation N/A
COGNITION THERAPEUTICS INC
Price$0.98
Model IV—
P/IV—
Limited data — see page
CHRS
Valuation N/A
Coherus Oncology, Inc.
Price$1.33
Model IV—
P/IV—
Market implies +57.0%/yr
vs model +2.0% · above model
CING
Valuation N/A
Cingulate Inc.
Price$5.17
Model IV—
P/IV—
Limited data — see page
CINGW
Valuation N/A
Cingulate Inc.
Price$0.01
Model IV—
P/IV—
Limited data — see page
CLDI
Valuation N/A
Calidi Biotherapeutics, Inc.
Price$1.17
Model IV—
P/IV—
Limited data — see page
CLDX
Valuation N/A
Celldex Therapeutics, Inc.
Price$39.18
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
CLGN
Valuation N/A
CollPlant Biotechnologies Ltd
Price$3.40
Model IV—
P/IV—
Market implies +60.5%/yr
vs model +2.0% · above model
CLLS
Valuation N/A
Cellectis S.A.
Price$3.10
Model IV—
P/IV—
Limited data — see page
CLNN
Valuation N/A
Clene Inc.
Price$3.57
Model IV—
P/IV—
Market implies +100.5%/yr
vs model +2.0% · above model
CLPT
Valuation N/A
ClearPoint Neuro, Inc.
Price$13.72
Model IV—
P/IV—
Market implies +45.5%/yr
vs model +22.7% · above model
CLYM
Valuation N/A
Climb Bio, Inc.
Price$14.25
Model IV—
P/IV—
Limited data — see page
CMMB
Valuation N/A
Chemomab Therapeutics Ltd.
Price$2.58
Model IV—
P/IV—
Limited data — see page
CMND
Valuation N/A
Clearmind Medicine Inc.
Price$0.97
Model IV—
P/IV—
Limited data — see page
CMPS
Valuation N/A
COMPASS Pathways plc
Price$14.54
Model IV—
P/IV—
Limited data — see page
CMPX
Valuation N/A
Compass Therapeutics, Inc.
Price$2.00
Model IV—
P/IV—
Market implies +82.9%/yr
vs model +15.0% · above model
CNSP
Valuation N/A
CNS Pharmaceuticals, Inc.
Price$5.84
Model IV—
P/IV—
Limited data — see page
CNTB
Valuation N/A
Connect Biopharma Holdings Ltd
Price$2.04
Model IV—
P/IV—
Market implies +63.9%/yr
vs model +15.0% · above model
CNTN
Valuation N/A
Canton Strategic Holdings, Inc.
Price$2.11
Model IV—
P/IV—
Limited data — see page
CNTX
Valuation N/A
Context Therapeutics Inc.
Price$0.35
Model IV—
P/IV—
Limited data — see page
COAG
Valuation N/A
Hemab Therapeutics Holdings, Inc.
Price$39.40
Model IV—
P/IV—
Limited data — see page
COCP
Valuation N/A
Cocrystal Pharma, Inc.
Price$1.24
Model IV—
P/IV—
Limited data — see page
COGT
Valuation N/A
Cogent Biosciences, Inc.
Price$33.41
Model IV—
P/IV—
Limited data — see page
COYA
Valuation N/A
Coya Therapeutics, Inc.
Price$4.38
Model IV—
P/IV—
Market implies +21.5%/yr
vs model +15.0% · above model
CPRX
Deeply undervalued
CATALYST PHARMACEUTICALS, INC.
Price$31.49
Model IV$82.62
P/IV0.38
Discount 62%
Return to IV: +162.4%
Market implies +6.0%/yr
vs model +25.0% · below model
CRBU
Valuation N/A
Caribou Biosciences, Inc.
Price$1.27
Model IV—
P/IV—
Market implies +64.6%/yr
vs model +3.8% · above model
CRDF
Valuation N/A
Cardiff Oncology, Inc.
Price$1.21
Model IV—
P/IV—
Market implies +77.6%/yr
vs model +13.4% · above model
CRDL
Valuation N/A
Cardiol Therapeutics Inc.
Price$2.00
Model IV—
P/IV—
Limited data — see page